Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
<h4>Background</h4>Gemcitabine and pemetrexed have been used as maintenance therapy. However, few systematic reviews and meta-analyses have assessed their effects in the newest studies. This systematic review and meta-analysis were conducted to assess the role of gemcitabine and pemetrex...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0149247&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850110764806832128 |
|---|---|
| author | Xingsheng Hu Ke Pu Xuqin Feng Shimin Wen Xi Fu Cuihua Guo Wenwu He |
| author_facet | Xingsheng Hu Ke Pu Xuqin Feng Shimin Wen Xi Fu Cuihua Guo Wenwu He |
| author_sort | Xingsheng Hu |
| collection | DOAJ |
| description | <h4>Background</h4>Gemcitabine and pemetrexed have been used as maintenance therapy. However, few systematic reviews and meta-analyses have assessed their effects in the newest studies. This systematic review and meta-analysis were conducted to assess the role of gemcitabine and pemetrexed in the maintenance treatment of non-small-cell lung carcinoma (NSCLC).<h4>Methods</h4>We performed a literature search using PubMed, EMBASE and Cochrane library databases from their inceptions to September 16, 2015. We also searched the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) databases from 2008 to 2015. Two authors independently extracted the data. The Cochrane Collaboration's risk of bias graph was used to assess the risk of bias. The GRADE system was used to assess the grading of evidence, and a meta-analysis was conducted using Stata 11.0 software.<h4>Results</h4>Eleven randomized controlled trial (RCT) studies were collected. Ten studies were included in the meta-analysis and divided into the following 4 groups: gemcitabine vs. best supportive care (BSC)/observation, pemetrexed vs. BSC/placebo, pemetrexed + bevacizumab vs. bevacizumab and pemetrexed vs. bevacizumab. Gemcitabine exhibited significantly improved progression-free survival (PFS) compared with BSC (hazard ratio (HR) = 0.62, p = 0.000). Pemetrexed exhibited significantly improved PFS (HR = 0.54, p = 0.000) and OS (HR = 0.75, p = 0.000) compared with BSC. Pemetrexed + bevacizumab almost exhibited significantly improved PFS (HR = 0.71, p = 0.051) compared with bevacizumab. Pemetrexed exhibited no improvement in PFS or overall survival (OS) compared with bevacizumab. Regarding the grade, the GRADE system indicated that the gemcitabine group was "MODERATE", the pemetrexed group was "HIGH", and both the pemetrexed + bevacizumab vs. bevacizumab groups and pemetrexed vs. B groups were "LOW".<h4>Conclusions</h4>Gemcitabine or pemetrexed compared with BSC/observation/placebo significantly improved PFS or OS. Whether pemetrexed + bevacizumab compared with bevacizumab alone significantly improves PFS requires further investigation. |
| format | Article |
| id | doaj-art-cef53403e81046e9a5c5f7f3bd34876f |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-cef53403e81046e9a5c5f7f3bd34876f2025-08-20T02:37:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01113e014924710.1371/journal.pone.0149247Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Xingsheng HuKe PuXuqin FengShimin WenXi FuCuihua GuoWenwu He<h4>Background</h4>Gemcitabine and pemetrexed have been used as maintenance therapy. However, few systematic reviews and meta-analyses have assessed their effects in the newest studies. This systematic review and meta-analysis were conducted to assess the role of gemcitabine and pemetrexed in the maintenance treatment of non-small-cell lung carcinoma (NSCLC).<h4>Methods</h4>We performed a literature search using PubMed, EMBASE and Cochrane library databases from their inceptions to September 16, 2015. We also searched the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) databases from 2008 to 2015. Two authors independently extracted the data. The Cochrane Collaboration's risk of bias graph was used to assess the risk of bias. The GRADE system was used to assess the grading of evidence, and a meta-analysis was conducted using Stata 11.0 software.<h4>Results</h4>Eleven randomized controlled trial (RCT) studies were collected. Ten studies were included in the meta-analysis and divided into the following 4 groups: gemcitabine vs. best supportive care (BSC)/observation, pemetrexed vs. BSC/placebo, pemetrexed + bevacizumab vs. bevacizumab and pemetrexed vs. bevacizumab. Gemcitabine exhibited significantly improved progression-free survival (PFS) compared with BSC (hazard ratio (HR) = 0.62, p = 0.000). Pemetrexed exhibited significantly improved PFS (HR = 0.54, p = 0.000) and OS (HR = 0.75, p = 0.000) compared with BSC. Pemetrexed + bevacizumab almost exhibited significantly improved PFS (HR = 0.71, p = 0.051) compared with bevacizumab. Pemetrexed exhibited no improvement in PFS or overall survival (OS) compared with bevacizumab. Regarding the grade, the GRADE system indicated that the gemcitabine group was "MODERATE", the pemetrexed group was "HIGH", and both the pemetrexed + bevacizumab vs. bevacizumab groups and pemetrexed vs. B groups were "LOW".<h4>Conclusions</h4>Gemcitabine or pemetrexed compared with BSC/observation/placebo significantly improved PFS or OS. Whether pemetrexed + bevacizumab compared with bevacizumab alone significantly improves PFS requires further investigation.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0149247&type=printable |
| spellingShingle | Xingsheng Hu Ke Pu Xuqin Feng Shimin Wen Xi Fu Cuihua Guo Wenwu He Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE |
| title | Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| title_full | Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| title_fullStr | Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| title_full_unstemmed | Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| title_short | Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| title_sort | role of gemcitabine and pemetrexed as maintenance therapy in advanced nsclc a systematic review and meta analysis of randomized controlled trials |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0149247&type=printable |
| work_keys_str_mv | AT xingshenghu roleofgemcitabineandpemetrexedasmaintenancetherapyinadvancednsclcasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT kepu roleofgemcitabineandpemetrexedasmaintenancetherapyinadvancednsclcasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xuqinfeng roleofgemcitabineandpemetrexedasmaintenancetherapyinadvancednsclcasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT shiminwen roleofgemcitabineandpemetrexedasmaintenancetherapyinadvancednsclcasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xifu roleofgemcitabineandpemetrexedasmaintenancetherapyinadvancednsclcasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT cuihuaguo roleofgemcitabineandpemetrexedasmaintenancetherapyinadvancednsclcasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT wenwuhe roleofgemcitabineandpemetrexedasmaintenancetherapyinadvancednsclcasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |